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Nuclear receptors link gender 
dimorphism of renal disease 
progression
Y Guan1,2
Profound gender differences in the progression of chronic kidney 
disease (CKD) remain poorly understood. Differential expression 
of the genes for male- and female-specific proteins in the kidney 
has been proposed to account for this clinical phenomenon. Lu and 
colleagues provide evidence that the signaling pathways of the 
nuclear receptors ERα, AR and PPARα are associated with gender 
differences in CKD progression.
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Chronic kidney disease (CKD) represents 
a major social, economic, and health 
problem in the world. Current pharma-
cological agents, including angiotensin-
converting enzyme inhibitors and 
angiotensin II receptor blockers, benefi t 
only a sub-population of CKD patients. 
Novel therapeutic approaches based on 
mechanistic elucidation of renal function 
loss are therefore urgently needed.
It has long been known that in female 
CKD patients, deterioration of renal 
function is much slower than in male 
patients, which suggests that male- 
and female-specifi c genes may play an 
important role in modulating the func-
tion of the kidney. A 2.2-year follow-up 
of the 840 participants in the Modifi -
cation of Diet in Renal Disease study 
revealed that female patients displayed 
less proteinuria and lower serum creati-
nine levels for given glomerular fi ltra-
tion rates than male patients, and the 
rate of decline in glomerular fi ltration 
rate was signifi cantly slower in women. 
A metaanalysis involving 11 345 CKD 
patients further confi rmed that women 
with non-diabetic CKD of various eti-
ologies show a much slower decline in 
renal function over time than do men.1 
Also, this protective eff ect in females 
is markedly lost aft er menopause.2 In 
various animal models of CKD, males 
display accelerated progression of renal 
damage as compared with females. In 
5/6 nephrectomized rats, castration pro-
tected against the development of pro-
teinuria, tubulointerstitial damage, and 
renal fi bronectin accumulation in males 
but not in females.3 Administration of 
estrogen to aging male rats or sponta-
neously hyperlipidemic rats ameliorated 
proteinuria and glomerular fi brosis.4 
Collectively, these observations clearly 
point to a gender diff erence in progres-
sion of renal injury in subjects with 
CKD. However, whether the presence of 
androgen or the absence of estrogen, or 
both factors combined, account for this 
disparity in renal disease progression is 
debatable. Th e mechanisms by which 
sex hormones regulate renal homeosta-
sis are not yet fully understood.
Th e sex hormones estrogen and testo-
sterone exert biological actions mainly 
via their corresponding nuclear recep-
tors — estrogen receptor (ER) and 
androgen receptor (AR). Both ER and 
AR belong to the superfamily of nuclear 
receptor transcription factors, consist-
ing of 49 transcription factors. Nuclear 
receptors govern the expression of genes 
involved in a diversity of biological proc-
esses, including reproduction, energy 
metabolism, lipid homeostasis, infl am-
mation, and cell proliferation and dif-
ferentiation.5 AR and ERα are expressed 
in the kidney, where activation of both 
may mediate the eff ect of androgen and 
estrogen on renal function. Previous 
studies involving a transgenic model of 
renin-dependent hypertension (mRen2 
transgenic rats) clearly demonstrated a 
role for AR in accelerating renal injury.4 
An AR-selective antagonist, fl utamide, 
not only modestly attenuated hyperten-
sion but also completely reversed renal 
histological changes and albuminuria 
in this model. Consistently, mutation 
of AR (testicular feminization muta-
tion (tfm)) resulted in lower blood 
pressure and reduced proteinuria in 
mRen2 transgenic rats.4 Lu et al.6 (this 
issue) now provide the fi rst evidence of 
renal induction of AR expression in 5/6 
nephrectomized male rats, which may 
account for the rapid deterioration of 
renal function that they observed. AR 
may therefore represent a promising 
therapeutic target for CKD treatment.
Although estrogens clearly confer 
significant renal protection in CKD 
subjects,1,2 the underlying mecha-
nism remains largely unknown. Sev-
eral elegant studies at the cellular level 
showed that estradiol reverses trans-
forming growth factor-β1-stimulated 
mesangial collagen IV expression and 
collagen I production via a casein kinase 
2/Sp1 mechanism and a mitogen-
a c t i v a t e d  p r o t e i n  k i n a s e / A P 1 
signaling pathway, respectively.4 Fur-
thermore, estrogen treatment also 
results in enhanced metalloproteinase-
2 activity in a mitogen-activated pro-
tein kinase/AP2-dependent manner.4 
Th ese eff ects of female sex hormones 
on mesangial cells may suppress extra-
cellular matrix accumulation and pro-
mote extracellular matrix degradation, 
thereby improving glomerulosclerosis. 
In light of these results, ER may repre-
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sent a molecular basis for the renopro-
tective eff ect seen in females, although 
an ER-independent mechanism(s) can-
not be excluded.
Lu and colleagues6 contribute a novel 
and important study of sexual diff er-
ences in CKD with potential clinical 
implications. In comparing the expres-
sion levels of ERα in male and female 
remnant kidneys, the authors found, 
for the fi rst time, that female kidneys 
showed much less of a decrease in ERα 
gene expression than male kidneys. Fur-
thermore, the authors present the fi rst 
evidence in male remnant kidneys that 
renal ERα expression levels, rather than 
circulating 17β-estradiol concentrations, 
are associated with multiple markers of 
CKD progression, including glomerular 
fi ltration rate, creatinine clearance, and 
proteinuria. Th ese observations sup-
port the idea that ER may be a critical 
determinant of CKD severity, and they 
provide a convincing explanation for 
why the male kidney rather than the 
female kidney has greater susceptibil-
ity to progressive renal injury. Although 
the authors’ study did not delineate the 
underlying mechanisms mediating ERα 
suppression in CKD kidneys, the fi nd-
ings suggest that selective activation of 
renal ERα might represent a rational 
maneuver to treat CKD in men and 
postmenopausal women.
Peroxisome proliferator-activated 
receptors (PPARs) form a subfamily of 
the nuclear receptor superfamily. Th ree 
PPAR isoforms exist, designated PPARα, 
PPARβ/δ, and PPARγ.7 Th e expression 
of each subtype of PPARs is tissue spe-
cifi c. PPARα is predominantly expressed 
in tissues with high energy demand, 
including liver, heart, and kidney. In the 
kidney, PPARα is selectively abundant in 
proximal tubule cells, where its activa-
tion is essential in fatty acid metabolism, 
energy homeostasis, and anti-infl am-
matory regulation. PPARα agonists 
signifi cantly improve but PPARα gene 
defi ciency markedly accelerates renal 
injury in many kidney diseases, includ-
ing diabetic nephropathy, cisplatin-
induced acute renal failure, and the 5/6 
nephrectomy model of chronic renal 
disease.8,9 Th ese observations suggest 
that PPARα could serve as an important 
renoprotective factor contributing to 
gender dimorphism of renal disease pro-
gression. To test this hypothesis, Lu and 
colleagues6 examined the expression of 
PPARα in normal and nephrectomized 
rat kidneys of both sexes. Renal PPARα 
expression was decreased in both male 
and female remnant kidneys but was 
much lower in male than in female kid-
neys. Importantly, the authors showed 
a tight negative correlation between the 
level of PPARα and its target gene acyl-
CoA oxidase and multiple markers of 
CKD in both sexes. Th ese fi ndings pro-
vide the fi rst line of evidence that renal 
PPARα transcriptional activity may be 
one of the key renoprotective factors 
involved in disease progression of CKD. 
Th e lower level of PPARα expression in 
male than in female remnant kidneys 
may therefore imply that PPARα may 
be another nuclear receptor determin-
ing the greater susceptibility of the male 
kidney than the female kidney to accel-
erated decline of renal function.
To study further the role of PPARα 
in gender dimorphism of CKD, Lu and 
colleagues6 focused on the role of cyto-
chrome P450 4a1 (Cyp4a1), another 
well-documented PPARα target gene. 
Consistently, they found a higher 
Cyp4a1 expression in nephrectomized 
females than in males. Furthermore, they 
observed a negative correlation between 
the expression of renal Cyp4a1 and that 
of various infl ammatory and apoptotic 
markers, especially in nephrectomized 
females. These findings significantly 
extend our understanding of the role 
of Cyp4a1 in the kidney. In addition to 
its previously reported hemodynamic 
eff ect,10 Cyp4a1 may be a potent anti-
infl ammatory and antiapoptotic factor 
downstream of the PPARα receptor in 
the diseased kidney.
In conclusion, Lu and co-workers6 
have provided valuable evidence that 
nuclear receptors may play a key role in 
gender diff erences in CKD progression. 
Th e alteration of ERα, AR, and PPARα 
pathways, together with changes in 
other transcription factors, including 
aryl hydrocarbon receptor and Wilms 
tumor 1, demonstrated in this study, 
may exert renoprotective eff ects on the 
female kidney during CKD. Although 
the article by Lu and colleagues6 rep-
resents an excellent first step toward 
understanding sexual dimorphism of 
renal disease progression, several basic 
questions remain: Do ERα, AR, and 
PPARα function independently or in 
concert? Do other nuclear receptors 
also contribute to the marked gender 
disparity in CKD? And what biological 
actions do these nuclear receptor sign-
aling pathways mediate in the kidney? 
Further studies are required to compare 
the expression profi les of all 49 nuclear 
receptors in the male and female kid-
ney and uncover the molecular events 
determined by each nuclear receptor in 
renal tissue. Such study will off er a sim-
ple but powerful way to obtain highly 
relational information about the roles of 
these receptors in gender dimorphism 
of renal disease progression.
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